Humacyte director granted 80,000 stock options

Humacyte, Inc. director Susan Richards Windham-Bannister received a grant of stock options covering 80,000 shares of common stock.

Rhea-AI Filing Summary

Humacyte, Inc. director Susan Richards Windham-Bannister received a grant of stock options covering 80,000 shares of common stock. The options carry an exercise price of 1.08 per share and expire on June 11, 2036.

According to the vesting terms, 25% of the option becomes exercisable on June 11, 2027. The remaining portion vests in equal monthly installments, with 1/48 of the option becoming exercisable on the 11th of each month through June 11, 2030. Following this grant, she holds 80,000 stock options directly.

Insider Trade Summary

Grant/Award: 80,000 shares

Grant/Award 1 txn

Insider Windham-Bannister Susan Richards

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (right to buy)	80,000	$0.00	$0.00

Holdings After Transaction: Stock Options (right to buy) — 80,000 contracts (Direct)

Footnotes (1)

1. F1. The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030.

Key Figures

Options granted: 80,000 options Exercise price: 1.08 per share Expiration date: June 11, 2036 +3 more

6 metrics

Options granted 80,000 options Grant of stock options to director

Exercise price 1.08 per share Conversion or exercise price of options

Expiration date June 11, 2036 Option term end date

Underlying shares 80,000 shares Common stock underlying the options

Initial vesting 25% on June 11, 2027 First vesting tranche of options

Subsequent vesting schedule 1/48 monthly to June 11, 2030 Remaining vesting pattern after initial tranche

Key Terms

Stock Options (right to buy), conversion or exercise price, expiration date, Grant, award, or other acquisition

4 terms

Stock Options (right to buy) financial

"Stock Options (right to buy)"

conversion or exercise price financial

"conversion_or_exercise_price": "1.0800""

expiration date financial

"expiration_date": "2036-06-11T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Humacyte (HUMA) disclose in this Form 4 filing?

Humacyte reported that director Susan Richards Windham-Bannister received a grant of stock options for 80,000 shares of common stock. These options were awarded as a compensation-related acquisition, not an open-market purchase or sale of existing shares.

How many Humacyte (HUMA) stock options were granted to the director?

The director was granted stock options covering 80,000 shares of Humacyte common stock. This entire 80,000-option position is shown as held directly following the transaction, indicating it reflects her current option holdings from this specific grant.

What is the exercise price and expiration for the Humacyte (HUMA) options?

The stock options have an exercise price of 1.08 per share and expire on June 11, 2036. This means the director can purchase Humacyte common stock at 1.08 per share any time after vesting and before the June 11, 2036 expiration date.

When do the newly granted Humacyte (HUMA) options start vesting?

The first 25% of the option grant becomes exercisable on June 11, 2027. After that date, 1/48 of the total option grant vests on the 11th of each month, continuing this monthly schedule until full vesting on June 11, 2030.

Are the Humacyte (HUMA) option grants an open-market transaction?

No, the filing describes the transaction as a grant or award acquisition of stock options. This is a compensation-related award from Humacyte, not an open-market purchase or sale of common stock on a securities exchange by the director.

How is ownership of the Humacyte (HUMA) options recorded for the director?

The Form 4 lists the 80,000 stock options as directly owned by the director. The ownership code is shown as "D" for direct ownership, with no footnote indicating that the options are held through a separate entity or trust.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 06:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Windham-Bannister Susan Richards

(Last) (First) (Middle)

2525 EAST NORTH CAROLINA

HIGHWAY 54

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Humacyte, Inc. [ HUMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	$1.08	06/11/2026		A		80,000		(1)	06/11/2036	Common Stock	80,000	$0	80,000	D

Explanation of Responses:

1. The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030.

	/s/ Susan Richards Windham-Bannister by Dale A. Sander as Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)